[Cognitive disorders in Behçet's disease]. / Kognitivnye narusheniia pri bolezni Bekhcheta.

AIM: To study the prevalence of cognitive disorders (CD) and clinical/pathogenetic correlations of CD in patients with Behçet's Disease (BD). MATERIAL AND METHODS: One hundred and six BD patients were enrolled in the study. The majority of patients were natives of the North Caucasus (51.9%). Mean age was 33.3±0.98 years, mean illness duration 148.5±10.4 months. All the patients met the criteria of the International Study Group for BD (1990) classification. The disease activity was assessed by scoring system BDCAF. A diagnosis of a mental disorder (MD) was established by the psychiatrist in accordance with the ICD-10 using a semi-structured interview. The Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HAM-A), a pathopsychological method 'Pictograms', clinical/psychological methods for assessment of cognitive functions (memory, attention concentration, logic thinking) were administered. Brain MRI was done in 44 (41.5%) BD patients. The study was conducted in the frames of the interdisciplinary program 'Stress factors and mental disorders in immune-mediated inflammatory rheumatic diseases'. RESULTS: CD of mild to moderate severity were diagnosed in 82 (77.4%) and anxiety-depressive disorders in 81 (76.4%) of BD patients. The patients with CD were older compared to patients without cognitive disorders (34.3±1.07 vs 29.0±2.14, p=0.006). Patients with CD were most often (84.1% vs 50.0%, p=0.001) diagnosed with anxiety-depressive disorder (anxiety, chronic/recurrent depression). MADRS scores were higher (16.1±0.74 vs 12.2±1.06, p=0.005) though did not exceed the moderate level. The impact of chronic psychosocial stressors was detected more often in CD patients. MRI results showed that the frequency of chronic multifocal, predominantly subcortical, changes in the white matter was higher in CD patients. CONCLUSION: CD are characteristic of most patients with BD. They are associated with the age, anxiety-depressive disorders, chronic stressors and minor brain multifocal subcortical parenchymal MRI lesions.

Dna is a New Target of Parp3.

Most members of the poly(ADP-ribose)polymerase family, PARP family, have a catalytic activity that involves the transfer of ADP-ribose from a beta-NAD+-molecule to protein acceptors. It was recently discovered by Talhaoui et al. that DNA-dependent PARP1 and PARP2 can also modify DNA. Here, we demonstrate that DNA-dependent PARP3 can modify DNA and form a specific primed structure for further use by the repair proteins. We demonstrated that gapped DNA that was ADP-ribosylated by PARP3 could be ligated to double-stranded DNA by DNA ligases. Moreover, this ADP-ribosylated DNA could serve as a primed DNA substrate for PAR chain elongation by the purified proteins PARP1 and PARP2 as well as by cell-free extracts. We suggest that this ADP-ribose modification can be involved in cellular pathways that are important for cell survival in the process of double-strand break formation.

[Psychotraumatic factors and anxiety-depressive spectrum disorders in Behcet's disease: the interdisciplinary study].

OBJECTIVE: To determine the frequency and variants of anxiety-depressive spectrum disorders (ADSD) in Behcet's disease (BD) and the effects of psychotraumatic factors, personality and clinical symptoms of the rheumatic disease. MATERIAL AND METHODS: Authors examined 60 patients with confirmed BD diagnosis made according to ISGBD criteria. The degree of BD activity was assessed using BDCAF index. The disease severity was ranged according to Ch. Zouboulis classification. All patients underwent complex rheumatologic, psychopathologic and psychological examinations. Childhood psychological trauma and stress factors before BD were analyzed. RESULTS: Most of the patients (86.7%) were diagnosed with a wide spectrum of ICD-10 ADSD: dysthymia (33.3%), recurrent depressive disorders (28.3%) mild or moderate depressive episode (11.7%), generalized anxiety disorder (6.7%), adjustment disorder with anxiety-depressive syndrome (6.7%). Mental disorders were not identified only in 13.3% of patients. The frequency of cognitive impairment (CI) was 88.3%, including 42.7% with mild CI. BD activity, ADSD severity and as well as factors not-related to disease contributed to CI development and severity. Psychological trauma during childhood and adolescence were found in 35 (58.3%) of patients. BD with early onset was recorded more often in the group with psychological trauma at the age <7 years compared to the group without psychological trauma. Treatment adherence was noted in most patients (70%) with BD and ADSD. CONCLUSION: The results confirm the need of timely diagnosis and adequate treatment of ADSD in patients with BD to improve treatment adherence and prognosis of disease.